NASDAQ · SLGL
Healthcare · Biotechnology
$84.04
Up+$3.15 (+3.74%)
Updated Aug 14, 2026, 3:05 PM
SID Score
3.4/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
SLGL closed at $84.04 after 21 trading sessions, up 7.63% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 13, 2026 | $71.85 | $84.60 | $71.80 | $84.04 | 77.88K |
| Aug 12, 2026 | $80.405 | $80.405 | $70.81 | $71.50 | 52.3K |
| Aug 11, 2026 | $84.00 | $84.40 | $77.0701 | $77.92 | 49.83K |
| Aug 10, 2026 | $88.42 | $90.72 | $83.81 | $84.74 | 84.32K |
| Aug 7, 2026 | $88.78 | $88.78 | $81.37 | $88.00 | 46.38K |
| Aug 6, 2026 | $88.78 | $90.00 | $86.3701 | $86.90 | 86.13K |
| Aug 5, 2026 | $85.89 | $89.67 | $85.6101 | $88.00 | 66.81K |
| Aug 4, 2026 | $83.60 | $85.40 | $81.065 | $84.495 | 40.1K |
| Aug 3, 2026 | $83.27 | $84.32 | $81.54 | $81.99 | 87.19K |
| Jul 31, 2026 | $86.52 | $90.40 | $82.25 | $82.25 | 74.06K |
| Jul 30, 2026 | $83.21 | $85.80 | $81.49 | $85.19 | 42.34K |
| Jul 29, 2026 | $84.23 | $85.69 | $79.84 | $82.545 | 54.35K |
| Jul 28, 2026 | $77.51 | $84.10 | $77.10 | $83.07 | 53.15K |
| Jul 27, 2026 | $82.36 | $85.985 | $79.77 | $79.83 | 47.21K |
| Jul 24, 2026 | $79.92 | $83.70 | $77.10 | $81.96 | 24.52K |
| Jul 23, 2026 | $84.19 | $87.72 | $79.66 | $80.55 | 30.82K |
| Jul 22, 2026 | $91.70 | $93.74 | $83.62 | $84.30 | 43.33K |
| Jul 21, 2026 | $79.31 | $90.1999 | $79.31 | $89.74 | 57.85K |
| Jul 20, 2026 | $83.64 | $84.45 | $79.41 | $80.10 | 77.58K |
| Jul 17, 2026 | $77.68 | $86.90 | $77.68 | $83.20 | 40.56K |
| Jul 16, 2026 | $77.51 | $82.01 | $74.55 | $78.08 | 101.92K |
The latest Smart Investors Daily articles mentioning SLGL.
SLGL research
Company profile and research snapshot.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 20, 2026 | HC Wainwright & Co. | Buy | — |
| Jun 24, 2026 | Mizuho | Outperform | — |
| Jan 20, 2026 | HC Wainwright & Co. | Buy | — |
| Dec 22, 2025 | HC Wainwright & Co. | Buy | — |
| Oct 27, 2025 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Jul 20, 2026
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Sol-Gel Technologies (NASDAQ:SLGL) with a Buy and maintains $110 price target.
Benzinga · Jun 24, 2026
Wall Street analysts changed outlook on top names, see all changes on Benzinga's analyst ratings page. Check out views on BB, SLGL, PRCT, OGE, TTWO.
Benzinga · Jun 24, 2026
Mizuho analyst Uy Ear initiates coverage on Sol-Gel Technologies (NASDAQ:SLGL) with a Outperform rating and announces Price Target of $285.
SeekingAlpha · Jan 16, 2026
Sol-Gel Technologies is now rated 'Hold' due to reliance on a single late-stage asset and limited pipeline depth. Read the latest analysis on SLGL stock here.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SLGL.
